NEWS
MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
FOR IMMEDIATE RELEASE West Chester, PA, and Singapore, September 12, 2023 — Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage…
Read more MTTI Announces the Appointment of Dr. Jerry Huang to the Clinical Team
Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore receiveHSA approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
FOR IMMEDIATE RELEASE West Chester, PA, and Singapore, August 2, 2023 — Molecular Targeting Technologies, Inc. (MTTI), and its…
MTTI Highlights Promising One-Year Follow-Up on Ebtate Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion
FOR IMMEDIATE RELEASE West Chester, PA June 21, 2023 — Molecular Targeting Technologies, Inc. (MTTI) announced promising results from…
MTTI Announces Favorable Three-Year Follow-Up for EBTATE in Neuroendocrine Tumors
FOR IMMEDIATE RELEASE West Chester, PA June 19, 2023 — Molecular Targeting Technologies, Inc. (MTTI) announced favorable findings of…
Read more MTTI Announces Favorable Three-Year Follow-Up for EBTATE in Neuroendocrine Tumors
MTTI obtains FDA allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer
FOR IMMEDIATE RELEASE West Chester, PA December 8, 2022, 6:01 am Eastern Standard Time (Business Wire)– Molecular Targeting Technologies,…
MTTI Receives Chinese Patent for EVATHERA Technology
FOR IMMEDIATE RELEASE West Chester, Pennsylvania, December 6, 2022 — Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of…
Read more MTTI Receives Chinese Patent for EVATHERA Technology
ITM and MTTI Sign Clinical Supply Agreement for n.c.a. Lutetium-177
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Molecular
Ready to learn more?
Reach out to us to learn more about EvaThera, MTTI, and the future of radiopharmaceuticals
